HTTP 200 OK
Allow: GET
Content-Type: application/json
Vary: Accept
{
"count": 1478259,
"next": "https://lda.senate.gov/api/v1/filings/?format=api&ordering=-registrant__name&page=2",
"previous": null,
"results": [
{
"url": "https://lda.senate.gov/api/v1/filings/130a7604-c528-4781-a842-0ec1d47e1422/?format=api",
"filing_uuid": "130a7604-c528-4781-a842-0ec1d47e1422",
"filing_type": "Q2",
"filing_type_display": "2nd Quarter - Report",
"filing_year": 2021,
"filing_period": "second_quarter",
"filing_period_display": "2nd Quarter (Apr 1 - June 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/130a7604-c528-4781-a842-0ec1d47e1422/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": "110000.00",
"expenses_method": "a",
"expenses_method_display": "Method A - Reporting amounts using LDA definitions only",
"posted_by_name": "Anna Jones",
"dt_posted": "2021-07-20T11:38:10.457000-04:00",
"termination_date": null,
"registrant": {
"id": 401106060,
"url": "https://lda.senate.gov/api/v1/registrants/401106060/?format=api",
"house_registrant_id": 401106060,
"name": "ZYMERGEN INC.",
"description": "Biofacturing company",
"address_1": "5980 Horton Street",
"address_2": "Suite 105",
"address_3": null,
"address_4": null,
"city": "Emeryville",
"state": "CA",
"state_display": "California",
"zip": "94608",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "ANNA OSTERLIND",
"contact_telephone": "+1 573-424-9497",
"dt_updated": "2021-08-26T09:05:32.693342-04:00"
},
"client": {
"id": 210500,
"url": "https://lda.senate.gov/api/v1/clients/210500/?format=api",
"client_id": 12,
"name": "ZYMERGEN INC.",
"general_description": null,
"client_government_entity": false,
"client_self_select": true,
"state": "CA",
"state_display": "California",
"country": "US",
"country_display": "United States of America",
"ppb_state": "CA",
"ppb_state_display": "California",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2021-03-23"
},
"lobbying_activities": [
{
"general_issue_code": "MAN",
"general_issue_code_display": "Manufacturing",
"description": "Issues related to domestic biomanufacturing investment; pharmaceutical supply chain resilience; nominations; biomedicine, biotech, and the bioeconomy",
"foreign_entity_issues": "Foreign entities identified on form LD-1 have an interest in the lobbying issues.",
"lobbyists": [
{
"lobbyist": {
"id": 101171,
"prefix": null,
"prefix_display": null,
"first_name": "ANNA",
"nickname": null,
"middle_name": null,
"last_name": "JONES",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 11,
"name": "Executive Office of the President (EOP)"
},
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 21,
"name": "Office of Science & Technology Policy (OSTP)"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/28bd30a0-ecd9-4a2f-a99f-7f82939142b5/?format=api",
"filing_uuid": "28bd30a0-ecd9-4a2f-a99f-7f82939142b5",
"filing_type": "Q1",
"filing_type_display": "1st Quarter - Report",
"filing_year": 2021,
"filing_period": "first_quarter",
"filing_period_display": "1st Quarter (Jan 1 - Mar 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/28bd30a0-ecd9-4a2f-a99f-7f82939142b5/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": "80000.00",
"expenses_method": "a",
"expenses_method_display": "Method A - Reporting amounts using LDA definitions only",
"posted_by_name": "Anna Jones",
"dt_posted": "2021-06-25T10:25:11.317000-04:00",
"termination_date": null,
"registrant": {
"id": 401106060,
"url": "https://lda.senate.gov/api/v1/registrants/401106060/?format=api",
"house_registrant_id": 401106060,
"name": "ZYMERGEN INC.",
"description": "Biofacturing company",
"address_1": "5980 Horton Street",
"address_2": "Suite 105",
"address_3": null,
"address_4": null,
"city": "Emeryville",
"state": "CA",
"state_display": "California",
"zip": "94608",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "ANNA OSTERLIND",
"contact_telephone": "+1 573-424-9497",
"dt_updated": "2021-08-26T09:05:32.693342-04:00"
},
"client": {
"id": 210500,
"url": "https://lda.senate.gov/api/v1/clients/210500/?format=api",
"client_id": 12,
"name": "ZYMERGEN INC.",
"general_description": null,
"client_government_entity": false,
"client_self_select": true,
"state": "CA",
"state_display": "California",
"country": "US",
"country_display": "United States of America",
"ppb_state": "CA",
"ppb_state_display": "California",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2021-03-23"
},
"lobbying_activities": [
{
"general_issue_code": "MAN",
"general_issue_code_display": "Manufacturing",
"description": "BARDA funds for public private partnerships; supply chain management",
"foreign_entity_issues": "Foreign entities identified on form LD-1 have an interest in the lobbying issues.",
"lobbyists": [
{
"lobbyist": {
"id": 101171,
"prefix": null,
"prefix_display": null,
"first_name": "ANNA",
"nickname": null,
"middle_name": null,
"last_name": "JONES",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 11,
"name": "Executive Office of the President (EOP)"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/8a69677d-e8bc-4aab-b179-7df76fbb0c6e/?format=api",
"filing_uuid": "8a69677d-e8bc-4aab-b179-7df76fbb0c6e",
"filing_type": "RR",
"filing_type_display": "Registration",
"filing_year": 2021,
"filing_period": "first_quarter",
"filing_period_display": "1st Quarter (Jan 1 - Mar 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/8a69677d-e8bc-4aab-b179-7df76fbb0c6e/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Anna Osterlind Jones",
"dt_posted": "2021-06-15T06:00:45.223000-04:00",
"termination_date": null,
"registrant": {
"id": 401106060,
"url": "https://lda.senate.gov/api/v1/registrants/401106060/?format=api",
"house_registrant_id": 401106060,
"name": "ZYMERGEN INC.",
"description": "Biofacturing company",
"address_1": "5980 Horton Street",
"address_2": "Suite 105",
"address_3": null,
"address_4": null,
"city": "Emeryville",
"state": "CA",
"state_display": "California",
"zip": "94608",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "ANNA OSTERLIND",
"contact_telephone": "+1 573-424-9497",
"dt_updated": "2021-08-26T09:05:32.693342-04:00"
},
"client": {
"id": 210500,
"url": "https://lda.senate.gov/api/v1/clients/210500/?format=api",
"client_id": 12,
"name": "ZYMERGEN INC.",
"general_description": null,
"client_government_entity": false,
"client_self_select": true,
"state": "CA",
"state_display": "California",
"country": "US",
"country_display": "United States of America",
"ppb_state": "CA",
"ppb_state_display": "California",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2021-03-23"
},
"lobbying_activities": [
{
"general_issue_code": "MED",
"general_issue_code_display": "Medical/Disease Research/Clinical Labs",
"description": "Enhanced investment in biomanufacturing; investment in workforce development, infrastructure, and R&D for synthetic biology; shoring up manufacturing supply chains for critical pharmaceutical ingredients; supporting government investment in mRNA-based technologies",
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 101171,
"prefix": null,
"prefix_display": null,
"first_name": "ANNA",
"nickname": null,
"middle_name": null,
"last_name": "JONES",
"suffix": null,
"suffix_display": null
},
"covered_position": "USDA, Trade & For. Ag. Aff., Chief of Staff; USDA, Ag. Mark. Serv., Chief of Staff; USDA, Off. of Cong. Relations, Cong. & Policy Adv.; Sen. Blunt: Leg. Corr., Exec. Assistant to Chief of Staff, Staff Assistant, Intern; House Budget Comm., Intern",
"new": true
}
],
"government_entities": []
},
{
"general_issue_code": "MAN",
"general_issue_code_display": "Manufacturing",
"description": "Enhanced investment in biomanufacturing; investment in workforce development, infrastructure, and R&D for synthetic biology; shoring up manufacturing supply chains for critical pharmaceutical ingredients; supporting government investment in mRNA-based technologies",
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 101171,
"prefix": null,
"prefix_display": null,
"first_name": "ANNA",
"nickname": null,
"middle_name": null,
"last_name": "JONES",
"suffix": null,
"suffix_display": null
},
"covered_position": "USDA, Trade & For. Ag. Aff., Chief of Staff; USDA, Ag. Mark. Serv., Chief of Staff; USDA, Off. of Cong. Relations, Cong. & Policy Adv.; Sen. Blunt: Leg. Corr., Exec. Assistant to Chief of Staff, Staff Assistant, Intern; House Budget Comm., Intern",
"new": true
}
],
"government_entities": []
},
{
"general_issue_code": "SCI",
"general_issue_code_display": "Science/Technology",
"description": "Enhanced investment in biomanufacturing; investment in workforce development, infrastructure, and R&D for synthetic biology; shoring up manufacturing supply chains for critical pharmaceutical ingredients; supporting government investment in mRNA-based technologies",
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 101171,
"prefix": null,
"prefix_display": null,
"first_name": "ANNA",
"nickname": null,
"middle_name": null,
"last_name": "JONES",
"suffix": null,
"suffix_display": null
},
"covered_position": "USDA, Trade & For. Ag. Aff., Chief of Staff; USDA, Ag. Mark. Serv., Chief of Staff; USDA, Off. of Cong. Relations, Cong. & Policy Adv.; Sen. Blunt: Leg. Corr., Exec. Assistant to Chief of Staff, Staff Assistant, Intern; House Budget Comm., Intern",
"new": true
}
],
"government_entities": []
}
],
"conviction_disclosures": [],
"foreign_entities": [
{
"name": "SVF EXCALIBUR (CAYMAN) LIMITED",
"contribution": "0.00",
"ownership_percentage": "24.00",
"address": "190 Elgin Avenue, George Town",
"city": "Grand Cayman, KY1-9008",
"state": null,
"state_display": null,
"country": "KY",
"country_display": "Cayman Islands",
"ppb_city": null,
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "KY",
"ppb_country_display": "Cayman Islands"
}
],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/57e47cf0-6d01-4d8d-b40d-7949f977e829/?format=api",
"filing_uuid": "57e47cf0-6d01-4d8d-b40d-7949f977e829",
"filing_type": "4TY",
"filing_type_display": "4th Quarter - Termination (No Activity)",
"filing_year": 2019,
"filing_period": "fourth_quarter",
"filing_period_display": "4th Quarter (Oct 1 - Dec 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/57e47cf0-6d01-4d8d-b40d-7949f977e829/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "Madeline Scherwitzky",
"dt_posted": "2020-01-16T09:38:43.133000-05:00",
"termination_date": "2019-10-01",
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": 401104361,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2021-08-26T09:04:32.426228-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/cf1b0c39-b925-42bd-b037-10c532ddbfe8/?format=api",
"filing_uuid": "cf1b0c39-b925-42bd-b037-10c532ddbfe8",
"filing_type": "Q1",
"filing_type_display": "1st Quarter - Report",
"filing_year": 2017,
"filing_period": "first_quarter",
"filing_period_display": "1st Quarter (Jan 1 - Mar 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/cf1b0c39-b925-42bd-b037-10c532ddbfe8/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": "140000.00",
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "Paul Varki",
"dt_posted": "2017-04-19T17:20:30.473000-04:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": 401104361,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2021-08-26T09:04:32.426228-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Prescription drug abuse and misuse policy issues\nH.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids\nH.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids\nProvisions related to the reauthorization of the Prescription Drug User Fee Act\n1st Amendment/Communications with payors/off-label policy issues\nAbuse-deterrent opioid policy issues\nPain therapy access policy issues",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "CPT",
"general_issue_code_display": "Copyright/Patent/Trademark",
"description": "Provisions related to abuse-deterrent opioid exclusivity",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "MMM",
"general_issue_code_display": "Medicare/Medicaid",
"description": "Prescription drug abuse policy issues\nProvisions related to abuse-deterrent opioid formulary placement",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "ALC",
"general_issue_code_display": "Alcohol and Drug Abuse",
"description": "Issues related to DEA quotas of Schedule I and II controlled substances\nS. 524 (114th Congress): Provisions related to opioid treatment and abuse",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/a9a8ff48-bef7-4da6-9677-306dacd88376/?format=api",
"filing_uuid": "a9a8ff48-bef7-4da6-9677-306dacd88376",
"filing_type": "1AY",
"filing_type_display": "1st Quarter - Amendment (No Activity)",
"filing_year": 2019,
"filing_period": "first_quarter",
"filing_period_display": "1st Quarter (Jan 1 - Mar 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/a9a8ff48-bef7-4da6-9677-306dacd88376/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "E. Blair Clark-Schoeb",
"dt_posted": "2019-05-23T09:13:40.030000-04:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": 401104361,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2021-08-26T09:04:32.426228-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/d3c747ff-45a3-4c3d-aa78-10df3afcce2f/?format=api",
"filing_uuid": "d3c747ff-45a3-4c3d-aa78-10df3afcce2f",
"filing_type": "Q3",
"filing_type_display": "3rd Quarter - Report",
"filing_year": 2018,
"filing_period": "third_quarter",
"filing_period_display": "3rd Quarter (July 1 - Sep 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/d3c747ff-45a3-4c3d-aa78-10df3afcce2f/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": "164000.00",
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "Megan Timmins",
"dt_posted": "2018-10-19T13:52:45.973000-04:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": 401104361,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2021-08-26T09:04:32.426228-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [
{
"general_issue_code": "MMM",
"general_issue_code_display": "Medicare/Medicaid",
"description": "Prescription drug abuse policy issues\nProvisions related to abuse-deterrent opioid formulary placement\nProvisions related to abuse-deterrent opioid coverage and access in Medicare\nH.R. 5582, the Abuse Deterrent Access Act regarding access to abuse-deterrent opioids in Medicare\nS. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 72598,
"prefix": null,
"prefix_display": null,
"first_name": "EILEEN BLAIR",
"nickname": null,
"middle_name": null,
"last_name": "CLARK-SCHOEB",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 136,
"name": "Centers For Medicare and Medicaid Services (CMS)"
},
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Prescription drug abuse and misuse policy issues\nH.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids\nH.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology\nH.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids\nAbuse-deterrent opioid policy issues\nPain therapy access policy issues\nS. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 72598,
"prefix": null,
"prefix_display": null,
"first_name": "EILEEN BLAIR",
"nickname": null,
"middle_name": null,
"last_name": "CLARK-SCHOEB",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 136,
"name": "Centers For Medicare and Medicaid Services (CMS)"
},
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "ALC",
"general_issue_code_display": "Alcohol and Drug Abuse",
"description": "S. 524 (114th Congress): Provisions related to opioid treatment and abuse",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 72598,
"prefix": null,
"prefix_display": null,
"first_name": "EILEEN BLAIR",
"nickname": null,
"middle_name": null,
"last_name": "CLARK-SCHOEB",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 136,
"name": "Centers For Medicare and Medicaid Services (CMS)"
},
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/564497fe-374e-42e6-ac90-4adcd1143e7d/?format=api",
"filing_uuid": "564497fe-374e-42e6-ac90-4adcd1143e7d",
"filing_type": "Q4",
"filing_type_display": "4th Quarter - Report",
"filing_year": 2018,
"filing_period": "fourth_quarter",
"filing_period_display": "4th Quarter (Oct 1 - Dec 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/564497fe-374e-42e6-ac90-4adcd1143e7d/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": "26316.38",
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "E. Blair Clark-Schoeb",
"dt_posted": "2019-01-18T13:10:58.143000-05:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": 401104361,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2021-08-26T09:04:32.426228-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [
{
"general_issue_code": "MMM",
"general_issue_code_display": "Medicare/Medicaid",
"description": "Pain therapy access policy issues",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 72598,
"prefix": null,
"prefix_display": null,
"first_name": "EILEEN BLAIR",
"nickname": null,
"middle_name": null,
"last_name": "CLARK-SCHOEB",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 34,
"name": "Health & Human Services, Dept of (HHS)"
},
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Prescription drug abuse and misuse policy issues\nPain therapy access policy issues",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 72598,
"prefix": null,
"prefix_display": null,
"first_name": "EILEEN BLAIR",
"nickname": null,
"middle_name": null,
"last_name": "CLARK-SCHOEB",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 34,
"name": "Health & Human Services, Dept of (HHS)"
},
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "ALC",
"general_issue_code_display": "Alcohol and Drug Abuse",
"description": "None",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 72598,
"prefix": null,
"prefix_display": null,
"first_name": "EILEEN BLAIR",
"nickname": null,
"middle_name": null,
"last_name": "CLARK-SCHOEB",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 34,
"name": "Health & Human Services, Dept of (HHS)"
},
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/e27f6fde-67f9-405a-9143-6c828b2ba7a7/?format=api",
"filing_uuid": "e27f6fde-67f9-405a-9143-6c828b2ba7a7",
"filing_type": "Q4",
"filing_type_display": "4th Quarter - Report",
"filing_year": 2017,
"filing_period": "fourth_quarter",
"filing_period_display": "4th Quarter (Oct 1 - Dec 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/e27f6fde-67f9-405a-9143-6c828b2ba7a7/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": "143000.00",
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "Megan Timmins",
"dt_posted": "2018-01-11T11:29:16.237000-05:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": 401104361,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2021-08-26T09:04:32.426228-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [
{
"general_issue_code": "MMM",
"general_issue_code_display": "Medicare/Medicaid",
"description": "Prescription drug abuse policy issues\nProvisions related to abuse-deterrent opioid formulary placement\nProvisions related to abuse-deterrent opioid coverage and access in Medicare",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Prescription drug abuse and misuse policy issues\nH.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids\nAbuse-deterrent opioid policy issues\nPain therapy access policy issues",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "ALC",
"general_issue_code_display": "Alcohol and Drug Abuse",
"description": "S. 524 (114th Congress): Provisions related to opioid treatment and abuse",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/45d5eb85-7c71-496a-ac61-6807b82a5204/?format=api",
"filing_uuid": "45d5eb85-7c71-496a-ac61-6807b82a5204",
"filing_type": "Q3Y",
"filing_type_display": "3rd Quarter - Report (No Activity)",
"filing_year": 2019,
"filing_period": "third_quarter",
"filing_period_display": "3rd Quarter (July 1 - Sep 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/45d5eb85-7c71-496a-ac61-6807b82a5204/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "E. Blair Clark-Schoeb",
"dt_posted": "2019-10-10T16:04:43.863000-04:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": 401104361,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2021-08-26T09:04:32.426228-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/ffc4b0b4-0cec-4c30-aa73-e7eae0b9ce73/?format=api",
"filing_uuid": "ffc4b0b4-0cec-4c30-aa73-e7eae0b9ce73",
"filing_type": "Q2Y",
"filing_type_display": "2nd Quarter - Report (No Activity)",
"filing_year": 2019,
"filing_period": "second_quarter",
"filing_period_display": "2nd Quarter (Apr 1 - June 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/ffc4b0b4-0cec-4c30-aa73-e7eae0b9ce73/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "E. Blair Clark-Schoeb",
"dt_posted": "2019-07-12T14:46:24.230000-04:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": 401104361,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2021-08-26T09:04:32.426228-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/deb80fe1-0821-4b00-b5c8-6eb4126ab21f/?format=api",
"filing_uuid": "deb80fe1-0821-4b00-b5c8-6eb4126ab21f",
"filing_type": "Q3",
"filing_type_display": "3rd Quarter - Report",
"filing_year": 2017,
"filing_period": "third_quarter",
"filing_period_display": "3rd Quarter (July 1 - Sep 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/deb80fe1-0821-4b00-b5c8-6eb4126ab21f/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": "143000.00",
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "Megan Timmins",
"dt_posted": "2017-10-23T15:53:41.300000-04:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": 401104361,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2021-08-26T09:04:32.426228-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [
{
"general_issue_code": "MMM",
"general_issue_code_display": "Medicare/Medicaid",
"description": "Prescription drug abuse policy issues\nProvisions related to abuse-deterrent opioid formulary placement",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
},
{
"id": 12,
"name": "White House Office"
}
]
},
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Prescription drug abuse and misuse policy issues\nH.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids\nAbuse-deterrent opioid policy issues\nPain therapy access policy issues\nS. 1049, provisions related to physician education on abuse-deterrent opioid products",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
},
{
"id": 12,
"name": "White House Office"
}
]
},
{
"general_issue_code": "ALC",
"general_issue_code_display": "Alcohol and Drug Abuse",
"description": "S. 524 (114th Congress): Provisions related to opioid treatment and abuse",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
},
{
"id": 12,
"name": "White House Office"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/93d2b8fa-e651-4355-b621-c1d33cd152af/?format=api",
"filing_uuid": "93d2b8fa-e651-4355-b621-c1d33cd152af",
"filing_type": "Q1",
"filing_type_display": "1st Quarter - Report",
"filing_year": 2018,
"filing_period": "first_quarter",
"filing_period_display": "1st Quarter (Jan 1 - Mar 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/93d2b8fa-e651-4355-b621-c1d33cd152af/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": "178000.00",
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "Megan Timmins",
"dt_posted": "2018-04-20T13:37:20.173000-04:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": 401104361,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2021-08-26T09:04:32.426228-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [
{
"general_issue_code": "MMM",
"general_issue_code_display": "Medicare/Medicaid",
"description": "Prescription drug abuse policy issues\nProvisions related to abuse-deterrent opioid formulary placement\nProvisions related to abuse-deterrent opioid coverage and access in Medicare",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 136,
"name": "Centers For Medicare and Medicaid Services (CMS)"
},
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Prescription drug abuse and misuse policy issues\nH.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids\nH.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology\nH.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids\nAbuse-deterrent opioid policy issues\nPain therapy access policy issues",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 136,
"name": "Centers For Medicare and Medicaid Services (CMS)"
},
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "ALC",
"general_issue_code_display": "Alcohol and Drug Abuse",
"description": "S. 524 (114th Congress): Provisions related to opioid treatment and abuse",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 136,
"name": "Centers For Medicare and Medicaid Services (CMS)"
},
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/30eb5997-d604-4340-9c68-9b8fa2dda83f/?format=api",
"filing_uuid": "30eb5997-d604-4340-9c68-9b8fa2dda83f",
"filing_type": "Q2Y",
"filing_type_display": "2nd Quarter - Report (No Activity)",
"filing_year": 2019,
"filing_period": "second_quarter",
"filing_period_display": "2nd Quarter (Apr 1 - June 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/30eb5997-d604-4340-9c68-9b8fa2dda83f/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "E. Blair Clark-Schoeb",
"dt_posted": "2019-07-15T09:00:06.210000-04:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": 401104361,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2021-08-26T09:04:32.426228-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/c7072767-f123-4661-8fcf-4e9e044a95df/?format=api",
"filing_uuid": "c7072767-f123-4661-8fcf-4e9e044a95df",
"filing_type": "Q2",
"filing_type_display": "2nd Quarter - Report",
"filing_year": 2017,
"filing_period": "second_quarter",
"filing_period_display": "2nd Quarter (Apr 1 - June 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/c7072767-f123-4661-8fcf-4e9e044a95df/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": "180000.00",
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "Paul Varki",
"dt_posted": "2017-07-27T12:42:50.247000-04:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": 401104361,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2021-08-26T09:04:32.426228-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [
{
"general_issue_code": "MMM",
"general_issue_code_display": "Medicare/Medicaid",
"description": "Prescription drug abuse policy issues\nProvisions related to abuse-deterrent opioid formulary placement",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Prescription drug abuse and misuse policy issues\nH.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids\nH.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids\nH.R. 2430, provisions related to the reauthorization of the Prescription Drug User Fee Act\n1st Amendment/Communications with payors/off-label policy issues\nAbuse-deterrent opioid policy issues\nPain therapy access policy issues\nS. 1049, provisions related to physician education on abuse-deterrent opioid products",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "CPT",
"general_issue_code_display": "Copyright/Patent/Trademark",
"description": "Abuse-deterrent opioid exclusivity policy issues\nH.R. 2025, provisions related to abuse-deterrent opioid exclusivity",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "ALC",
"general_issue_code_display": "Alcohol and Drug Abuse",
"description": "Issues related to DEA quotas of Schedule I and II controlled substances\nS. 524 (114th Congress): Provisions related to opioid treatment and abuse",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/d092686d-10d3-453a-95b5-03f493731524/?format=api",
"filing_uuid": "d092686d-10d3-453a-95b5-03f493731524",
"filing_type": "RR",
"filing_type_display": "Registration",
"filing_year": 2017,
"filing_period": "first_quarter",
"filing_period_display": "1st Quarter (Jan 1 - Mar 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/d092686d-10d3-453a-95b5-03f493731524/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Madeline Scherwitzky",
"dt_posted": "2017-04-10T16:35:37-04:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": 401104361,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2021-08-26T09:04:32.426228-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [
{
"general_issue_code": "MED",
"general_issue_code_display": "Medical/Disease Research/Clinical Labs",
"description": "Abuse Deterrent Formulation(ADF)Legistlation",
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": true
}
],
"government_entities": []
},
{
"general_issue_code": "MMM",
"general_issue_code_display": "Medicare/Medicaid",
"description": "Abuse Deterrent Formulation(ADF)Legistlation",
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": true
}
],
"government_entities": []
},
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Abuse Deterrent Formulation(ADF)Legistlation",
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": true
}
],
"government_entities": []
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/95e61a76-255e-4869-9a86-611d8ecad6e8/?format=api",
"filing_uuid": "95e61a76-255e-4869-9a86-611d8ecad6e8",
"filing_type": "Q2",
"filing_type_display": "2nd Quarter - Report",
"filing_year": 2018,
"filing_period": "second_quarter",
"filing_period_display": "2nd Quarter (Apr 1 - June 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/95e61a76-255e-4869-9a86-611d8ecad6e8/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": "147000.00",
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "Megan Timmins",
"dt_posted": "2018-07-19T14:56:50.990000-04:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": 401104361,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2021-08-26T09:04:32.426228-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Prescription drug abuse and misuse policy issues\nH.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids\nH.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology\nH.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids\nAbuse-deterrent opioid policy issues\nPain therapy access policy issues\nS. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 136,
"name": "Centers For Medicare and Medicaid Services (CMS)"
},
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "MMM",
"general_issue_code_display": "Medicare/Medicaid",
"description": "Prescription drug abuse policy issues\nProvisions related to abuse-deterrent opioid formulary placement\nProvisions related to abuse-deterrent opioid coverage and access in Medicare\nH.R. 5582, the Abuse Deterrent Access Act regarding access to abuse-deterrent opioids in Medicare\nS. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 136,
"name": "Centers For Medicare and Medicaid Services (CMS)"
},
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "ALC",
"general_issue_code_display": "Alcohol and Drug Abuse",
"description": "S. 524 (114th Congress): Provisions related to opioid treatment and abuse",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 136,
"name": "Centers For Medicare and Medicaid Services (CMS)"
},
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/e8d64220-83b2-4231-bce6-913ce5183f58/?format=api",
"filing_uuid": "e8d64220-83b2-4231-bce6-913ce5183f58",
"filing_type": "MT",
"filing_type_display": "Mid-Year Termination",
"filing_year": 2000,
"filing_period": "mid_year",
"filing_period_display": "Mid-Year (Jan 1 - Jun 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/e8d64220-83b2-4231-bce6-913ce5183f58/print/",
"filing_document_content_type": "application/pdf",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": null,
"dt_posted": "2000-08-08T00:00:00-04:00",
"termination_date": null,
"registrant": {
"id": 42205,
"url": "https://lda.senate.gov/api/v1/registrants/42205/?format=api",
"house_registrant_id": null,
"name": "ZWEBEN, MURRAY",
"description": null,
"address_1": "601 13TH ST NW #370-SOUTH",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WASHINGTON",
"state": "DC",
"state_display": "District of Columbia",
"zip": "20005",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "",
"contact_telephone": "",
"dt_updated": "2021-08-26T08:49:36.009737-04:00"
},
"client": {
"id": 152488,
"url": "https://lda.senate.gov/api/v1/clients/152488/?format=api",
"client_id": 12,
"name": "ADVO",
"general_description": null,
"client_government_entity": null,
"client_self_select": null,
"state": null,
"state_display": null,
"country": "US",
"country_display": "United States of America",
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "1950-12-30"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/50c7a3bf-3bd3-494b-9c47-135afd3923dc/?format=api",
"filing_uuid": "50c7a3bf-3bd3-494b-9c47-135afd3923dc",
"filing_type": "YYY",
"filing_type_display": "Year-End Report (No Activity)",
"filing_year": 1999,
"filing_period": "year_end",
"filing_period_display": "Year-End (July 1 - Dec 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/50c7a3bf-3bd3-494b-9c47-135afd3923dc/print/",
"filing_document_content_type": "application/pdf",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": null,
"dt_posted": "2000-02-14T00:00:00-05:00",
"termination_date": null,
"registrant": {
"id": 42205,
"url": "https://lda.senate.gov/api/v1/registrants/42205/?format=api",
"house_registrant_id": null,
"name": "ZWEBEN, MURRAY",
"description": null,
"address_1": "601 13TH ST NW #370-SOUTH",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WASHINGTON",
"state": "DC",
"state_display": "District of Columbia",
"zip": "20005",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "",
"contact_telephone": "",
"dt_updated": "2021-08-26T08:49:36.009737-04:00"
},
"client": {
"id": 152488,
"url": "https://lda.senate.gov/api/v1/clients/152488/?format=api",
"client_id": 12,
"name": "ADVO",
"general_description": null,
"client_government_entity": null,
"client_self_select": null,
"state": null,
"state_display": null,
"country": "US",
"country_display": "United States of America",
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "1950-12-30"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/40674484-ab82-4807-807f-2cd580da7181/?format=api",
"filing_uuid": "40674484-ab82-4807-807f-2cd580da7181",
"filing_type": "MMY",
"filing_type_display": "Mid-Year Report (No Activity)",
"filing_year": 1999,
"filing_period": "mid_year",
"filing_period_display": "Mid-Year (Jan 1 - Jun 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/40674484-ab82-4807-807f-2cd580da7181/print/",
"filing_document_content_type": "application/pdf",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": null,
"dt_posted": "1999-08-16T00:00:00-04:00",
"termination_date": null,
"registrant": {
"id": 42205,
"url": "https://lda.senate.gov/api/v1/registrants/42205/?format=api",
"house_registrant_id": null,
"name": "ZWEBEN, MURRAY",
"description": null,
"address_1": "601 13TH ST NW #370-SOUTH",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WASHINGTON",
"state": "DC",
"state_display": "District of Columbia",
"zip": "20005",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "",
"contact_telephone": "",
"dt_updated": "2021-08-26T08:49:36.009737-04:00"
},
"client": {
"id": 152488,
"url": "https://lda.senate.gov/api/v1/clients/152488/?format=api",
"client_id": 12,
"name": "ADVO",
"general_description": null,
"client_government_entity": null,
"client_self_select": null,
"state": null,
"state_display": null,
"country": "US",
"country_display": "United States of America",
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "1950-12-30"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/eda952e7-4893-4df0-8f63-41736602117b/?format=api",
"filing_uuid": "eda952e7-4893-4df0-8f63-41736602117b",
"filing_type": "YY",
"filing_type_display": "Year-End Report",
"filing_year": 2006,
"filing_period": "year_end",
"filing_period_display": "Year-End (July 1 - Dec 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/eda952e7-4893-4df0-8f63-41736602117b/print/",
"filing_document_content_type": "application/pdf",
"income": "40000.00",
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": null,
"dt_posted": "2007-01-17T00:00:00-05:00",
"termination_date": null,
"registrant": {
"id": 32613,
"url": "https://lda.senate.gov/api/v1/registrants/32613/?format=api",
"house_registrant_id": 30299,
"name": "ZVI RAFIAH",
"description": "Consultant & Commentator on US Affairs",
"address_1": "20 MOTTA GUR STREET",
"address_2": null,
"address_3": "TELAVIV",
"address_4": " 6969420",
"city": null,
"state": null,
"state_display": null,
"zip": null,
"country": "IL",
"country_display": "Israel",
"ppb_country": "IL",
"ppb_country_display": "Israel",
"contact_name": "",
"contact_telephone": "",
"dt_updated": "2021-08-26T08:47:25.544486-04:00"
},
"client": {
"id": 140741,
"url": "https://lda.senate.gov/api/v1/clients/140741/?format=api",
"client_id": 113,
"name": "INSIGHTEC LTD",
"general_description": null,
"client_government_entity": null,
"client_self_select": null,
"state": null,
"state_display": null,
"country": "IL",
"country_display": "Israel",
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "IL",
"ppb_country_display": "Israel",
"effective_date": "2006-03-02"
},
"lobbying_activities": [
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": null,
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 32863,
"prefix": null,
"prefix_display": null,
"first_name": "ZVI",
"nickname": null,
"middle_name": null,
"last_name": "RAFIAH",
"suffix": null,
"suffix_display": null
},
"covered_position": "N/A",
"new": null
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/a7e0cca4-fe22-4a93-b71f-36e7bbb2a0ce/?format=api",
"filing_uuid": "a7e0cca4-fe22-4a93-b71f-36e7bbb2a0ce",
"filing_type": "RR",
"filing_type_display": "Registration",
"filing_year": 2006,
"filing_period": "mid_year",
"filing_period_display": "Mid-Year (Jan 1 - Jun 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/a7e0cca4-fe22-4a93-b71f-36e7bbb2a0ce/print/",
"filing_document_content_type": "application/pdf",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": null,
"dt_posted": "2006-04-05T00:00:00-04:00",
"termination_date": null,
"registrant": {
"id": 32613,
"url": "https://lda.senate.gov/api/v1/registrants/32613/?format=api",
"house_registrant_id": 30299,
"name": "ZVI RAFIAH",
"description": "Consultant & Commentator on US Affairs",
"address_1": "20 MOTTA GUR STREET",
"address_2": null,
"address_3": "TELAVIV",
"address_4": " 6969420",
"city": null,
"state": null,
"state_display": null,
"zip": null,
"country": "IL",
"country_display": "Israel",
"ppb_country": "IL",
"ppb_country_display": "Israel",
"contact_name": "",
"contact_telephone": "",
"dt_updated": "2021-08-26T08:47:25.544486-04:00"
},
"client": {
"id": 140741,
"url": "https://lda.senate.gov/api/v1/clients/140741/?format=api",
"client_id": 113,
"name": "INSIGHTEC LTD",
"general_description": null,
"client_government_entity": null,
"client_self_select": null,
"state": null,
"state_display": null,
"country": "IL",
"country_display": "Israel",
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "IL",
"ppb_country_display": "Israel",
"effective_date": "2006-03-02"
},
"lobbying_activities": [
{
"general_issue_code": "MED",
"general_issue_code_display": "Medical/Disease Research/Clinical Labs",
"description": null,
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 32863,
"prefix": null,
"prefix_display": null,
"first_name": "ZVI",
"nickname": null,
"middle_name": null,
"last_name": "RAFIAH",
"suffix": null,
"suffix_display": null
},
"covered_position": "N/A",
"new": true
}
],
"government_entities": []
},
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": null,
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 32863,
"prefix": null,
"prefix_display": null,
"first_name": "ZVI",
"nickname": null,
"middle_name": null,
"last_name": "RAFIAH",
"suffix": null,
"suffix_display": null
},
"covered_position": "N/A",
"new": true
}
],
"government_entities": []
}
],
"conviction_disclosures": [],
"foreign_entities": [
{
"name": "ELBIT ULTRASOUND BV",
"contribution": "0.00",
"ownership_percentage": null,
"address": null,
"city": null,
"state": null,
"state_display": null,
"country": "NL",
"country_display": "Netherlands",
"ppb_city": null,
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "NL",
"ppb_country_display": "Netherlands"
},
{
"name": "INSIGHTEC",
"contribution": "0.00",
"ownership_percentage": null,
"address": null,
"city": null,
"state": null,
"state_display": null,
"country": "IL",
"country_display": "Israel",
"ppb_city": null,
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "IL",
"ppb_country_display": "Israel"
}
],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/df6bfac4-f312-47d6-bc02-1b755bb72482/?format=api",
"filing_uuid": "df6bfac4-f312-47d6-bc02-1b755bb72482",
"filing_type": "RA",
"filing_type_display": "Registration - Amendment",
"filing_year": 2006,
"filing_period": "mid_year",
"filing_period_display": "Mid-Year (Jan 1 - Jun 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/df6bfac4-f312-47d6-bc02-1b755bb72482/print/",
"filing_document_content_type": "application/pdf",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": null,
"dt_posted": "2006-05-01T00:00:00-04:00",
"termination_date": null,
"registrant": {
"id": 32613,
"url": "https://lda.senate.gov/api/v1/registrants/32613/?format=api",
"house_registrant_id": 30299,
"name": "ZVI RAFIAH",
"description": "Consultant & Commentator on US Affairs",
"address_1": "20 MOTTA GUR STREET",
"address_2": null,
"address_3": "TELAVIV",
"address_4": " 6969420",
"city": null,
"state": null,
"state_display": null,
"zip": null,
"country": "IL",
"country_display": "Israel",
"ppb_country": "IL",
"ppb_country_display": "Israel",
"contact_name": "",
"contact_telephone": "",
"dt_updated": "2021-08-26T08:47:25.544486-04:00"
},
"client": {
"id": 140741,
"url": "https://lda.senate.gov/api/v1/clients/140741/?format=api",
"client_id": 113,
"name": "INSIGHTEC LTD",
"general_description": null,
"client_government_entity": null,
"client_self_select": null,
"state": null,
"state_display": null,
"country": "IL",
"country_display": "Israel",
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "IL",
"ppb_country_display": "Israel",
"effective_date": "2006-03-02"
},
"lobbying_activities": [
{
"general_issue_code": "MED",
"general_issue_code_display": "Medical/Disease Research/Clinical Labs",
"description": null,
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 32863,
"prefix": null,
"prefix_display": null,
"first_name": "ZVI",
"nickname": null,
"middle_name": null,
"last_name": "RAFIAH",
"suffix": null,
"suffix_display": null
},
"covered_position": "N/A",
"new": true
}
],
"government_entities": []
},
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": null,
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 32863,
"prefix": null,
"prefix_display": null,
"first_name": "ZVI",
"nickname": null,
"middle_name": null,
"last_name": "RAFIAH",
"suffix": null,
"suffix_display": null
},
"covered_position": "N/A",
"new": true
}
],
"government_entities": []
}
],
"conviction_disclosures": [],
"foreign_entities": [
{
"name": "INSIGHTEC",
"contribution": "0.00",
"ownership_percentage": null,
"address": null,
"city": null,
"state": null,
"state_display": null,
"country": "IL",
"country_display": "Israel",
"ppb_city": null,
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "IL",
"ppb_country_display": "Israel"
},
{
"name": "ELBIT ULTRASOUND BV",
"contribution": "0.00",
"ownership_percentage": null,
"address": null,
"city": null,
"state": null,
"state_display": null,
"country": "NL",
"country_display": "Netherlands",
"ppb_city": null,
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "NL",
"ppb_country_display": "Netherlands"
}
],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/7b1ce740-cef0-451d-be8b-b53ea30ed26a/?format=api",
"filing_uuid": "7b1ce740-cef0-451d-be8b-b53ea30ed26a",
"filing_type": "MTY",
"filing_type_display": "Mid-Year Termination (No Activity)",
"filing_year": 2007,
"filing_period": "mid_year",
"filing_period_display": "Mid-Year (Jan 1 - Jun 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/7b1ce740-cef0-451d-be8b-b53ea30ed26a/print/",
"filing_document_content_type": "application/pdf",
"income": "0.00",
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": null,
"dt_posted": "2007-07-09T00:00:00-04:00",
"termination_date": null,
"registrant": {
"id": 32613,
"url": "https://lda.senate.gov/api/v1/registrants/32613/?format=api",
"house_registrant_id": 30299,
"name": "ZVI RAFIAH",
"description": "Consultant & Commentator on US Affairs",
"address_1": "20 MOTTA GUR STREET",
"address_2": null,
"address_3": "TELAVIV",
"address_4": " 6969420",
"city": null,
"state": null,
"state_display": null,
"zip": null,
"country": "IL",
"country_display": "Israel",
"ppb_country": "IL",
"ppb_country_display": "Israel",
"contact_name": "",
"contact_telephone": "",
"dt_updated": "2021-08-26T08:47:25.544486-04:00"
},
"client": {
"id": 140741,
"url": "https://lda.senate.gov/api/v1/clients/140741/?format=api",
"client_id": 113,
"name": "INSIGHTEC LTD",
"general_description": null,
"client_government_entity": null,
"client_self_select": null,
"state": null,
"state_display": null,
"country": "IL",
"country_display": "Israel",
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "IL",
"ppb_country_display": "Israel",
"effective_date": "2006-03-02"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/12c59bd6-368b-440c-a724-36a0d0a4449f/?format=api",
"filing_uuid": "12c59bd6-368b-440c-a724-36a0d0a4449f",
"filing_type": "MM",
"filing_type_display": "Mid-Year Report",
"filing_year": 2006,
"filing_period": "mid_year",
"filing_period_display": "Mid-Year (Jan 1 - Jun 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/12c59bd6-368b-440c-a724-36a0d0a4449f/print/",
"filing_document_content_type": "application/pdf",
"income": "20000.00",
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": null,
"dt_posted": "2006-07-24T00:00:00-04:00",
"termination_date": null,
"registrant": {
"id": 32613,
"url": "https://lda.senate.gov/api/v1/registrants/32613/?format=api",
"house_registrant_id": 30299,
"name": "ZVI RAFIAH",
"description": "Consultant & Commentator on US Affairs",
"address_1": "20 MOTTA GUR STREET",
"address_2": null,
"address_3": "TELAVIV",
"address_4": " 6969420",
"city": null,
"state": null,
"state_display": null,
"zip": null,
"country": "IL",
"country_display": "Israel",
"ppb_country": "IL",
"ppb_country_display": "Israel",
"contact_name": "",
"contact_telephone": "",
"dt_updated": "2021-08-26T08:47:25.544486-04:00"
},
"client": {
"id": 140741,
"url": "https://lda.senate.gov/api/v1/clients/140741/?format=api",
"client_id": 113,
"name": "INSIGHTEC LTD",
"general_description": null,
"client_government_entity": null,
"client_self_select": null,
"state": null,
"state_display": null,
"country": "IL",
"country_display": "Israel",
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "IL",
"ppb_country_display": "Israel",
"effective_date": "2006-03-02"
},
"lobbying_activities": [
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": null,
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 32863,
"prefix": null,
"prefix_display": null,
"first_name": "ZVI",
"nickname": null,
"middle_name": null,
"last_name": "RAFIAH",
"suffix": null,
"suffix_display": null
},
"covered_position": "N/A",
"new": null
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
}
]
}
